Neohesperidin induces cellular apoptosis in human breast adenocarcinoma MDA-MB-231 cells via activating the Bcl-2/Bax-mediated signaling pathway

Natural Product Communications

Volumn 7, Issue 11, 2012, Pages 1475-1478

  Xu, Fei ^a,b   Zang, Jia ^a   Chen, Daozhen ^a   Zhang, Ting ^a   Zhan, Huiying ^a   Lu, Mudan ^a   Zhuge, Hongxiang ^b  

^a Department of Laboratory Medicine   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Bax mediated signaling pathway; Cell apoptosis; MDA MB 231 cells; Neohesperidin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HESPERETIN; NEOHESPERIDIN; PROLACTIN RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RUTOSIDE; SCAVENGER; TAMOXIFEN;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURGERY; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHINESE MEDICINE; DOSE RESPONSE; DOWN REGULATION; DRUG STRUCTURE; FLOW CYTOMETRY; HERBAL MEDICINE; IC 50; IMMUNOBLOTTING; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIFOLIATE ORANGE; UPREGULATION;

EID: 84869779139     PISSN: 1934578X     EISSN: 15559475     Source Type: Journal    
DOI: 10.1177/1934578x1200701116     Document Type: Article

References (30)

1. Fritah A, Saucier C, De Wever O, Bracke M, Bieche I, Lidereau R, Gespach C, Drouot S, Redeuilh G, Sabbah M. (2008) Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Molecular and Cellular Biology, 28, 1114-1123. (Pubitemid 351160067)
2. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR. (2009) Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One, 4, e6146.
3. Wilmsen PK, Spada DS, Salvador M. (2005) Antioxidant activity of the flavonoid hesperidin in chemical and biological systems. Journal of Agricultural and Food Chemistry, 53, 4757-4761. (Pubitemid 40937593)
4. Emim JA, Oliveira AB, Lapa AJ. (1994) Pharmacological evaluation of the anti-inflammatory activity of a citrus bioflavonoid, hesperidin, and the isoflavonoids, duartin and claussequinone, in rats and mice. Journal of Pharmacy and Pharmacology, 46, 118-122. (Pubitemid 24070840)
5. Kawaguchi K, Kikuchi S, Hasunuma R, Maruyama H, Ryll R, Kumazawa Y. (2004) Suppression of infection-induced endotoxin shock in mice by a citrus flavanone naringin. Planta Medica, 70, 17-22. (Pubitemid 38233907)
6. So FV, Guthrie N, Chambers AF, Moussa M, Carroll KK. (1996) Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nurtition and Cancer, 26, 167-181. (Pubitemid 26300196)
7. Lee JH, Lee SH, Kim YS, Jeong CS. (2009) Protective effects of neohesperidin and poncirin isolated from the fruits of Poncirus trifoliata on potential gastric disease. Phytotherapy Research, 23, 1748-1753.
8. Berkarda B, Koyuncu H, Soybir G, Baykut F. (1998) Inhibitory effect of hesperidin on tumour initiation and promotion in mouse skin. Research in Experimental Medicine, 198, 93-99. (Pubitemid 28431912)
9. Park HJ, Kim MJ, Ha E, Chung JH. (2008) Apoptotic effect of hesperidin through caspase3 activation in human colon cancer cells, SNU-C4. Phytomedicine, 15, 147-151. (Pubitemid 350297903)
10. Kamaraj S, Ramakrishnan G, Anandakumar P, Jagan S, Devaki T. (2009) Antioxidant and anticancer efficacy of hesperidin in benzo(a)pyrene induced lung carcinogenesis in mice. Investigational New Drugs, 27, 214-222.
11. Tanaka T. (1997) Chemoprevention of human cancer: biology and therapy. Critical Reviews in Oncology/ Hematology, 25, 139-174.
12. Hirano T, Abe K, Gotoh M, Oka K. (1995) Citrus flavone tangeretin inhibits leukaemic HL-60 cell growth partially through induction of apoptosis with less cytotoxicity on normal lymphocytes. British Journal of Cancer, 72, 1380-1388. (Pubitemid 26002646)
13. Wu CC, Chung JG, Tsai SJ, Yang JH, Sheen LY. (2004) Differential effects of allyl sulfides from garlic essential oil on cell cycle regulation in human liver tumor cells. Food and Chemical Toxicology, 42, 1937-1947. (Pubitemid 39421495)
14. Bradford MM. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anayitical Biochemistry, 72, 248-254.
15. Bollag DM RM, Edelstein SJ. (1996) Protein Methods (Second Edition) Wiley-Liss, Inc, New York.
16. Borska S, Drag-Zalesinska M, Wysocka T, Sopel M, Dumanska M, Zabel M, Dziegiel P. (2010) Antiproliferative and pro-apoptotic effects of quercetin on human pancreatic carcinoma cell lines EPP85-181P and EPP85-181RDB. Folia Histochemica et Cytobiologica, 48, 222-229.
17. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M. (1999) Antiproliferative activity of flavonoids on several cancer cell lines. Bioscience, Biotechnology, and Biochemistry, 63, 896-899. (Pubitemid 129562768)
18. Manthey JA, Guthrie N. (2002) Antiproliferative activities of citrus flavonoids against six human cancer cell lines. Journal of Agricultural and Food Chemistry, 50, 5837-5843. (Pubitemid 35155302)
19. Fridman JS, Lowe SW. (2003) Control of apoptosis by p53. Oncogene, 22, 9030-9040. (Pubitemid 38121703)
20. Arun B, Kilic G, Yen C, Foster B, Yardley D, Gaynor R, Ashfaq R. (2003) Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes. Cancer, 98, 2554-2559. (Pubitemid 37509517)
21. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G. (1995) Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. British Journal of Cancer, 71, 1003-1007.
22. Nakamura S, Akazawa K, Kinukawa N, Yao T, Tsuneyoshi M. (1996) Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma. Human Pathology, 27, 225-233. (Pubitemid 26078900)
23. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. (1994) Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Research, 54, 2095-2097. (Pubitemid 24138678)
24. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9, 1799-1805. (Pubitemid 24163411)
25. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B. (1996) p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. Journal of Clinical Oncology, 14, 1604-1610. (Pubitemid 26134219)
26. Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA. (2006) Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene, 25, 7305-7310. (Pubitemid 44809096)
27. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D. (1994) Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene, 9, 1791-1798. (Pubitemid 24163410)
28. Caelles C, Helmberg A, Karin M. (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature, 370, 220-223. (Pubitemid 24236778)
29. Kirkin V, Joos S, Zornig M. (2004) The role of Bcl-2 family members in tumorigenesis. Biochimica et Biophysica Acta, 1644, 229-249. (Pubitemid 38281277)
30. Manion MK, Hockenbery DM. (2003) Targeting BCL-2-related proteins in cancer therapy. Cancer Biology and Therapy, 2, S105-S114.